According to the results of clinical trials of TIM3 in MDS/AML/CMML (NCT04878432,NCT04812548,NCT03066648,NCT03946670), the combination of TIM3 inhibitors with demethylating drugs (decitabine or azacitidine) and/or small-molecule targeted drugs or immune checkpoint inhibitors is better than monotherapy. Here, HAVCR2 is linked to chronic myelomonocytic leukemia.